Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

Peer Review reports

Original Submission
23 Jun 2021	Submitted	Original manuscript
27 Sep 2021	Reviewed	Reviewer Report - Vladislav Semiglazov
11 Oct 2021	Reviewed	Reviewer Report
3 Nov 2021	Author responded	Author comments - Jin Zhang
Resubmission - Version 2
3 Nov 2021	Submitted	Manuscript version 2
Publishing
8 Nov 2021	Editorially accepted
6 Dec 2021	Article published	10.1186/s12885-021-09050-6

Back to article page